1. Epidemiology & Oncological Overview
Cutaneous Melanoma represents the most lethal form of skin neoplasm, responsible for over 75% of skin cancer deaths despite accounting for only 5% of all cutaneously diagnosed malignancies. Originating in melanocytes situated along the basal layer of the epidermis, melanoma exhibits rapid metastatic potential when invasion extends through the basement membrane into the vascularized papillary and reticular dermis.
2. The Clinical ABCDE Diagnostic Framework
Early identification remains the cornerstone of survival, with localized in situ lesions (Stage IA) exhibiting a 5-year survival rate exceeding 99%:
- A — Asymmetry: Splitting the lesion along horizontal or vertical axes reveals non-congruent halves.
- B — Border Irregularity: Margins appear scalloped, notched, indistinct, or sharply jagged.
- C — Color Variegation: Multi-pigment presence within the lesion — mixtures of tan, dark brown, jet black, red, white (depigmentation/regression), or blue hues.
- D — Diameter: Lesion dimension exceeding 6 millimeters across (standard pencil eraser reference).
- E — Evolution: Any documented progression in surface texture, elevation, size, pruritus, or spontaneous ulceration/bleeding.
3. Dermoscopy Hallmarks & Histopathological Staging
Dermoscopy increases diagnostic accuracy by up to 35% compared to naked-eye visual inspection:
- Atypical Pigment Network: Thickened, unevenly spaced reticular lines ending abruptly at the lesion periphery.
- Blue-White Veil: Confluent blue hue with ground-glass opacity indicating melanin in the deep dermis beneath hyperkeratosis.
- Breslow Depth: The single most vital histopathological prognostic indicator, measuring vertical micro-invasion in millimeters from the granular layer to the deepest malignant melanocyte.
4. Surgical Excision & Modern Systemic Therapies
Standard care mandates full-thickness excisional biopsy with 1–3mm margins, followed by wide local excision (1cm to 2cm margins dependent on Breslow thickness), sentinel lymph node biopsy (SLNB), and modern checkpoint inhibitors (anti-PD-1 pembrolizumab, nivolumab) or BRAF/MEK targeted combinations.